By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Molecular diagnostics firm SIRS-Lab today announced a collaboration with Pfizer Pharma focused on sepsis diagnostics and treatment.

The firms will initially evaluate the clinical impact of using molecular-based tests for diagnosis of severe fungal blood stream infections, as well as the pharmacoeconomics of such an approach.

Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The partially reinstated US travel ban leaves space for uncertainty for researchers, Nature News says.

Researchers find a number of traits differ by sex and could affect mouse model studies, according to Reuters.

Tweaking the skin microbiome could help address some skin conditions, the New York Times reports.

In PNAS this week: DNA methylation profiles of tumor tissue, gene dynamics in prokaryotes, and more.